No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 16 of the 40 quarters in the window, leaving 24 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.8x · 10Y median 10.8x · 12th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:05:37.733Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Ardelyx, Inc. (ARDX) stock was $3.32 as of Oct 6, 2026, 10:05 AM EDT, down 2.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -35.4% · 3-year avg -5.7%/yr · 5-year avg +20.9%/yr
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines.
Biotechnology · Waltham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
-0.01
Revenue Est.
$129.03M
Last Quarter Results
EPS
$-0.07
vs Estimate
$-0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ARDX | $818.90M | $3.31 | -2.21% | -35.42% | +20.95% | -0.20% | N/A |
| 2INMD | $811.05M | $14.11 | -0.14% | -6.70% | -27.48% | N/A | vs ARDX |
| 3GYRE | $808.29M | $7.25 | -1.36% | +0.14% | -0.34% | -14.92% | vs ARDX |
| 4JBIO | $831.35M | $13.66 | -2.91% | +58.45% | -52.65% | N/A | vs ARDX |
| 5ALMS | $834.17M | $6.76 | -1.20% | +69.72% | N/A | N/A | vs ARDX |
| 6APMD | $844.65M | $21.21 | -2.48% | N/A | N/A | N/A | vs ARDX |
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$120.88M
vs Estimate
$121.04M
Consensus Rating
Based on 10 analysts
Average Price Target
$12.90
+289.1% upside
Low
$8.00
Current
$3.31
High
$18.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.03 | $-0.01 | $0.00 | 6 |
| Quarter ending Dec 2026 | $-0.02 | $0.04 | $0.11 | 6 |
| Quarter ending Mar 2027 | $-0.05 | $-0.05 | $-0.05 | 2 |
| Quarter ending Jun 2027 | $0.02 | $0.03 | $0.03 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.24 | $-0.18 | $-0.09 | 8 |
| FY 2027 | $0.03 | $0.26 | $0.68 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $124.17M | $129.22M | $132.85M | 7 |
| Quarter ending Dec 2026 | $137.41M | $144.19M | $153.75M | 7 |
| Quarter ending Mar 2027 | $109.53M | $115.63M | $123.52M | 3 |
| Quarter ending Jun 2027 | $131.07M | $138.38M | $147.82M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $481.62M | $488.78M | $494.04M | 8 |
| FY 2027 | $573.15M | $623.90M | $747.22M | 8 |
